Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2009.01.069 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
J Allergy Clin Immunol
December 2020
Department of Dermatology, School of Medicine, University of Utah, Salt Lake City, Utah.
Article Synopsis
- A study was conducted to evaluate the effectiveness and safety of mepolizumab, an anti-IL-5 therapy, in treating patients with hypereosinophilic syndrome (HES) compared to a placebo.
- The trial included 108 patients across 39 centers and found that those receiving mepolizumab had a 50% lower rate of flares (worsening symptoms) than those on placebo.
- Both treatment groups had similar rates of adverse events, suggesting that mepolizumab is effective in reducing symptom flares without introducing new safety concerns.
Management of Loeffler's Endocarditis With Bivalvular Involvement and a FIP1L1/PDGFRA-Negative Mutation.
Can J Cardiol
December 2016
Department of Cardiology, Institut universitaire de cardiologie et de pneumologie de Québec, Laval University, Québec City, Québec, Canada.
Hypereosinophilic syndromes (HESs) are a group of disorders characterized by end-organ damage caused by eosinophilic infiltration. We present a patient with idiopathic HES with severe tricuspid and mitral regurgitation secondary to Loeffler's endocarditis. In addition to prednisone, imatinib therapy initially helped control the eosinophil count.
View Article and Find Full Text PDFRapid left ventricular thickening and thrombus caused by FIP1L1/PDGFRA-negative hypereosinophilic syndrome.
Tex Heart Inst J
March 2014
Division of Hematology, Chonbuk National University Hospital, Jeonju, Jeonbuk 561-712, Republic of Korea.
WEBSITE FEATURE
View Article and Find Full Text PDFLong-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
J Allergy Clin Immunol
February 2013
Department of Internal Medicine, Hôpital Erasme, Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Background: Hypereosinophilic syndromes (HESs) are chronic disorders that require long-term therapy to suppress eosinophilia and clinical manifestations. Corticosteroids are usually effective, yet many patients become corticosteroid refractory or develop corticosteroid toxicity. Mepolizumab, a humanized monoclonal anti-IL-5 antibody, showed corticosteroid-sparing effects in a double-blind, placebo-controlled study of FIP1L1/PDGFRA-negative, corticosteroid-responsive subjects with HESs.
View Article and Find Full Text PDFResponse to alemtuzumab in FIP1L1/PDGFRA-negative hypereosinophilic myocarditis on serial cardiac magnetic resonance imaging.
J Am Coll Cardiol
January 2012
Division of Cardiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!